# **ECRONICON**

# A New Possible Application of Transcranial Magnetic Stimulation: Case Report

# D Levi<sup>1</sup>, G Raffa<sup>2</sup>, M Periti<sup>3</sup> and G Broggi<sup>1,4,5\*</sup>

<sup>1</sup>Fondazione Istituto Europeo per le Neuroscienze, Italy

<sup>2</sup>U.O.C. Neurochirurgia e Dipartimento di Medicina Clinica e Sperimentale - Università di Messina, Italy

<sup>3</sup>Casa di Cura la Madonnina Milano, Milano, Italy

<sup>4</sup>Istituto Clinico Citta' Studi Milano, Milano, Italy

<sup>5</sup>Fond Istituto Neurologico C. Besta, Milano, Italy

\*Corresponding Author: G Broggi, Professor, Istituto Clinico Citta' Studi Milano, Milano, Italy.

Received: July 09, 2018; Published: October 27, 2018

# Abstract

**Background:** Trans Cranial Magnetic stimulation is a novel technique for non-invasive cerebral stimulation that is finding many application for neurologic and psychiatric disorders such as Parkinson disease and depression.

The Physical laws that underlie the TMS permit further applications such as drug delivery.

As a matter of fact according to the Biot Savart and Maxwell Faraday electromagnetic laws it is possible to concentrate magnetic substances like gadolinium in specific areas.

**Case Description:** A 67 year old woman underwent TMS for drug resistant depression. Casually she underwent to gadolinium enhanced MRI in the same day as she performed TMS. The result was of Gadolinium concentration on the same side of stimulation. *Keywords:* Blood; Brain Barrier; Chemotherapy; CNS Tumors; Depression; Psychiatric Disorders; Repetitive Transcranial Magnetic Stimulation

# Abbreviations

AMPA: α-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid; BECF: Brain Extra-Cellular Fluid; CNS: Central Nervous System; DPFC: Dorsolateral Pre-frontal Cortex; ECT: Electroconvulsive Therapy; ENG: Electronic Nerve Gathering; FDA: Food and Drug Administration; fMRI: Functional Magnetic Resonance Imaging; LTD: Long-term Depression; LTP: Long-term Potentiation; MEG: Magneto-Encephalography; MEP: Motor Evoked Potential; MRI: Magnetic Resonance Imaging; MDA: N-Methyl-D-Aspartate; PET: Positron Emission Tomography; PTSD: Post-traumatic Stress Disorders; rTMS: Repetitive Transcranial Magnetic Stimulation; TMS: Transcranial Magnetic Stimulation

# Introduction

Transcranial Magnetic Stimulation (TMS) relies on the possibility of using Faraday's law of electromagnetic induction to stimulate the brain, spinal cord and peripheral nerves by applying magnetic pulses in a non-invasive and painless manner (Barker Jalinous and Freeston 1985).

Repetitive Transcranial Stimulation (rTMS) is mostly used to inhibit or facilitate cortical activity [1-3], with the aim of studying brain functions the relation and changes of different cortical areas in cognitive and emotional behavior. The use of rTMS has been also experimental investigate and applied in different of psychiatric disorders [4].

The targeting of dorsolateral pre-frontal cortex (DFPC) as an alternative and coadjutant in depression treatment therapy, presently being one of the most experimented and recognized role of application of rTMS [5,6].

Experimental variations in different aspects of rTMS like targeting different areas, changes in laterality, technical protocols, and stimulation parameters and set up (FDA approved or not yet) have been showing some interesting results in treatment of anxiety, obsessive compulsive disorders, post-traumatic stress disorders (PTSD) and as an alternative to electroconvulsive therapy (ECT) for patients who do not respond to anti-depressive drugs [7]. Researches are also pointing out the role rTMS in the treatment of substance abuse disorders [5].

#### **Case Report**

This case report describes a clinical observation in a 67 year old female that has been diagnosed and treated for depression in the last 10 years. The decreasing therapeutical response to antidepressant drugs in the last year, has lead the psychiatrist in-charge of the patient, to take the decision of using rTMS as a coadjutant treatment for the issue of the patient, and the patient was referred to us.

The rTMS used for the treatment is a Duomag XT 100 system (citare il produttore) with an adapted coil to repetitive r TMS. The coil also has a cooling system for prolonged stimulation.

The treatment stimulation applied the FDA approved protocol with 40 pulses at frequency of 10 HZ for a total of 6000 pulses per session (3000 on the left, 3000 on the right) administered on the left DLFC (Dorso Lateral Frontal Cortex) as well as on the right side target because of the specific drug resistance history of the patient. The treatment was administered for 5 days in 6 weeks cycle treatment.

In the second week of treatment once completed the cycle of 3000 pulses on the left side in the target of DLFC the patient waiting for the right side stimulation reported a sudden intense headache, that faded away in few minutes. After an interval of two hours the patient was happy to complete the above mentioned cycle of stimulation on the right DLPC (3000 pulses), carried out without any further side effect.

When the day session was over, the patient underwent to a previously scheduled MRI with contrast enhancement because of a previously described cystic malformative brain lesion.

While executing the MRI we observed that the Gadolinium was majorly concentrated on the right side, the side where the stimulation was immediately before performed, with the two hours interval toward the previous left side stimulation.




Figure 1: These Figures show a major contrast enhancement on the right side.

#### **Physical and Basic principles of TMS**

The exact details of how TMS functions are still being explored and not completely clarified.

The cell membrane separates an electrical potential difference between intra-and extracellular space. The average transmembrane potential is about 70 mV. As known the intra cellular space potential is negative.

It has been shown that an applied magnetic field changes the cell membrane potential and activates a depolarization of the membrane that consequently activates the neuronal tissue.

Tailored electric fields for neuronal stimulation can be generated by electromagnetic induction. In transcranial magnetic stimulation a time-varying magnetic field generates a current flow in the neuronal tissue.

Several Tesla are needed in Trans cranial Magnetic Stimulation. These strong magnetic fields are generated brief current pulses of several kiloamperes and delivered to the neural tissue by a specific coil.

Trans Cranial Magnetic Stimulation uses the physical principle of electromagnetic induction to generate an electric current across the scalp, the skull and the neural tissue. A plastic-enclosed coil of wire is held next to the skull and when activated, produces a magnetic field oriented orthogonally to the plane of the coil. The magnetic field passes un -impeded through the skin, the skull, inducing an oppositely directed current in the brain. This current flow activates neural cells almost the same way as it would a current applied directly to the brain's cortical surface.

The ways in which the current passes through the neural tissue is difficult to track because of the brain's anatomical irregularity and electric fields and magnetism are not conducted uniformly. The magnetic field is comparable to the strength as a modern MRI up to 3 Tesla. The pulse generally reaches the depth in the brain tissue up to 5 centimeters. There are variants of TMS that reach more than 5 cm of depth.

The law of electromagnetism to which the TMS is referred to is Biot-Savart law. According to the Biot-Savart that a current that passes through a wire generates a magnetic field around the wire, following the formula.

$$\mathbf{B} = \frac{\mu_0}{4\pi} I \int_C \frac{d\mathbf{l} \times \hat{\mathbf{r}}}{r^2}$$

Transcranial Magnetic Stimulation is generated by a quickly discharging current that consequently produces a pulsed magnetic field between 2 and 3 T. By directing the pulsed magnetic field to a targeted area of the brain, it is possible to depolarize or hyperpolarize neurons membrane. The magnetic flux density generated by the pulsed current is explained by the Maxwell-Faraday equation [8-38].

$$\nabla\times {\bf E} = -\frac{\partial {\bf B}}{\partial t}$$

The generated electric field causes a change in the trans-membrane potential of the neuron, this variation can produce the depolarization or hyperpolarization of the neuron's membrane and so generating an action potential [36,37].

When a TMS coil is applied to the skull of a patient, according to what has been previously described, when the cerebral area stimulated is the site of primary motor cortex, the stimulation will produces muscle activity that can be recorded as a motor evoked potential (MEP) [8,9]. When the coil is applied on the occipital cortex, 'phosphenes are perceived by the patient. In most other areas of the cortex, there is no consciously experienced effect. The stimulation of particular cerebral areas affects the behavior (e.g. slower or fastened reaction time on a cognitive task).

Repetitive TMS produces longer-lasting effects which persist past the initial period of stimulation. The underlying mechanism of these effects is not clear: it is widely believed that this formal effect is due to changes in synaptic efficiency due to long-term potentiation (LTP) and long-term depression (LTD) [10,13]. Both of these mechanisms depend on synaptic receptors AMPA and NMDA.

The localization with TMS of eloquent or functional areas, as the motor one, has also been seen to correlate closely to MEG and also to fMRI data.

*Citation:* G Broggi., *et al.* "A New Possible Application of Transcranial Magnetic Stimulation: Case Report". *EC Neurology* 10.11 (2018): 1000-1005.

fMRI images, recorded during TMS of the motor cortex, have been found to match very closely with PET modifications induced by voluntary movements of the hand muscles activated by TMS.

#### Conclusions

These observations allow the possibility to propose TMS novel application. As known one of the major aims in neuro-oncology is to reduce side effects of chemo-therapeutical drugs.

A constant problem in neuro-oncology is drug delivery to the cerebral lesion, with single dose reduction but with increase concentration in the lesion possibly only inside it.

The main difficulty to reach such result is the presence of the blood brain barrier:

- The blood-brain barrier (BBB) is a highly selective barrier that separates the blood, from the Central Nervous System (CNS) and from the brain extracellular fluid (BECF)
- The blood-brain barrier histologically is formed by various (endothelial and glial) cells connected by tight junctions with an extremely high electrical resistivity ( $0.1 \Omega \cdot m$ .). The blood-brain barrier allows the passage of water, some gases and lipid-soluble molecules by passive diffusion, as well as the selective and active transport of essential molecules like glucose and amino acids.

In conclusion, following our serendipity observation on this clinical case, the use of TMS could satisfy both request.

This study demonstrates that activating a magnetic field, by TMS, on the site of the lesion, it is possible to increase the concentration of a paramagnetic substance like gadolinium in the lesion. The coupling of therapeutically agents with a paramagnetic substrate may increase the possibility of better clinical results when applied to the CNS pathology.

# Acknowledgements

We thank for reviewing and editing the paper Alessandro Nocciola of the Neurophysiology services Australia and Lidia Franconeri for the literature review and arrangements.

# Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

# **Disclosure of Interest**

None.

#### **Bibliography**

- 1. Scibilia A., *et al.* "Resting-state fMR evidence of network reorganization induced by navigated transcranial magnetic repetitive stimulation in phantom limb pain". *Neurological Research* 40.4 (2018): 241-248.
- Raffa G., *et al.* "Surgery of language-eloquent tumors in patients not eligible for awake surgery: the impact of a protocol based on navigated transcranial magnetic stimulation on presurgical planning and language outcome, with evidence of tumor-induced intrahemispheric pl". *Clinical Neurology and Neurosurgery* 168 (2018): 127-139.
- 3. Raffa G., *et al.* "A Novel Technique for Region and Linguistic Specific nTMS-based DTI Fiber Tracking of Language Pathways in Brain Tumor Patients". *Frontiers in Neuroscience* 10 (2016): 552.
- 4. Siebner HR., et al. "Consensus paper: combining transcranial stimulation with neuroimaging". Brain Stimulation 2.2 (2009): 58-80.
- De Sousa A. "Repetitive transcranial magnetic stimulation (rTMS) in the management of alcohol dependence and other substance abuse disorders - emerging data and clinical relevance". *Basic and Clinical Neuroscience* 4.3 (2013): 89-93.
- 6. BD ACA. "Brain stimulation techniques in the treatment of refractory psychiatric disorders: Current and future directions". *Rivista di Psichiatria* 41.5 (2006): 289-300.

- 7. Dell'Osso B., *et al.* "Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression". *Bipolar Disorders* 11.1 (2009): 76-81.
- 8. Rizzo V., et al. "Preoperative functional mapping for rolandic brain tumor surgery". Neuroscience Letters 583 (2014): 136-141.
- 9. Mangraviti A., *et al.* "Practical assessment of preoperative functional mapping techniques: navigated transcranial magnetic stimulation and functional magnetic resonance imaging". *Neurological Sciences* 34.9 (2013): 1551-1557.
- 10. Raffa G., *et al.* "The Impact of Diffusion Tensor Imaging Fiber Tracking of the Corticospinal Tract Based on Navigated Transcranial Magnetic Stimulation on Surgery of Motor-Eloquent Brain Lesions". *Neurosurgery* (2017).
- 11. Conti A., *et al.* "Navigated transcranial magnetic stimulation for "somatotopic" tractography of the cortico-spinal tract". *Neurosurgery* 10.4 (2014): 542-554.
- 12. Raffa G., *et al.* "Functional Reconstruction of Motor and Language Pathways Based on Navigated Transcranial Magnetic Stimulation and DTI Fiber Tracking for the Preoperative Planning of Low Grade Glioma Surgery: A New Tool for Preservation and Restoration of Eloquent Network". *Acta Neurochirurgica Supplement* 124 (2017): 251-261.
- 13. Raffa G., *et al.* "nTMS-Based DTI Fiber Tracking of Motor Pathways". In: M. Krieg S, ed. *Navigated Transcranial Magnetic Stimulation in Neurosurgery*. Cham: Springer International Publishing (2017): 97-114.
- 14. Amiaz R., et al. "Brain stimulation in the study and treatment of addiction". Addiction 104.4 (2009): 653-660.
- 15. Baeken C., *et al.* "Baseline 'state anxiety' influences HPA-axis sensitivity to one sham controlled HF-rTMS session applied to the right dorsolateral prefrontal cortex". *Psychoneuroendocrinology* 36.1 (2009): 60-67.
- 16. Barr MS., *et al.* "Transcranial magnetic stimulation to understand the pathophysiology and treatment of substance use disorders". *Current Drug Abuse Reviews* 1.3 (2008): 328-339.
- 17. Bechara A. "Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective". *Nature Neuroscience* 8.11 (2005): 1458-1463.
- 18. Camprodon JA., *et al.* "One session of high frequency repetitive transcranial magnetic stimulation (rTMS) to the right prefrontal cortex transiently reduces cocaine craving". *Drug and Alcohol Dependence* 86.1 (2007): 91-94.
- 19. Chesher NJ., *et al.* "Chronic illness history of adults entering into treatment for co-occurring substance use disorders and other mental illnesses". *American Journal on Addiction* 21.1 (2011): 1-4.
- 20. Cho SS and Strafella AP. "rTMS on the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex". *PLoS One* 4.8 (2009): e6725.
- 21. Daskalakis B., *et al.* "The effects of repetitive transcranial magnetic stimulation on cortical inhibition in healthy human subjects". *Experimental Brain Research* 174.3 (2006): 403-412.
- 22. De Ridder D., *et al.* "Transient alcohol craving suppression by rTMS of dorsolateral anterior cingulate: an fMRI and LORETA EEG study". *Neuroscience Letters* 496.1 (2011): 5-10.
- 23. Fecteau S., et al. "Neuromodulation of decision-making in the addictive brain". Substance Use and Misuse 45.11 (2010): 1766-1786.
- 24. Fitzgerald PB., *et al.* "GABA and cortical inhibition in motor and non-motor regions using combined TMS-EEG: a time analysis". *Clinical Neurophysiology* 120.9 (2009): 1706-1710.
- 25. Goldstein RZ and Volkow ND. "Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex". *American Journal of Psychiatry* 159.10 (2002): 1642-1652.
- 26. Heinz A., et al. "Identifying the neural circuitry of alcohol craving and relapse vulnerability". Addiction Biology 14.1 (2009): 108-118.

- 27. Höppner J., et al. "Repetitive transcranial magnetic stimulation (rTMS) for treatment of alcohol dependence". *The World Journal of Biological Psychiatry* 12.1 (2011): 57-62.
- 28. Houben K., *et al.* "Resisting temptation: decreasing alcohol-related affect and drinking behavior by training response inhibition". *Drug and Alcohol Dependence* 116.1-3 (2011): 132-136.
- 29. Kalsi G., et al. "Unravelling the molecular mechanisms of alcohol dependence". Trends in Genetics 25.1 (2009): 49-55.
- 30. Koob GF. "Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit disorder". *Current Topics in Behavioural Neuroscience* 13 (2013): 3-30.
- 31. Koob GF and Volkow ND. "Neurocircuitry of addiction". *Neuropsychopharmacology* 35.1 (2010): 217-238.
- 32. Potenza MN and Taylor JR. "Found in translation: understanding impulsivity and related constructs through integrated pre-clinical and clinical research". *Biological Psychiatry* 66.8 (2009): 714-716.
- 33. Stalnaker TA and Takahashi YK. "A new perspective on the role of the orbitofrontal cortex in adaptive behavior". *Nature Reviews Neuroscience* 10.12 (2009): 885-892.
- 34. Siu EC and Tyndale RF. "Non-nicotinic therapies for smoking cessation". *Annual Reviews of Pharmacology and Toxicology* 47 (2007): 541-564.
- 35. Zhang XL., *et al.* "Clonidine improved laboratory-measured decision-making performance in abstinent heroin addicts". *PLos One* 7.1 (2012): e29084.
- 36. W Ross Adey. "Electromagnetic fields, the modulation of brain tissue functions A possible paradigm shift in biology". International Encyclopedia of Neuroscience Third Edition B. Smith and G. Adelman, editors. Elsevier, New York.
- Alexander Opitz., et al. "How the brain tissue shapes the electric field induced by transcranial magnetic stimulation". Neuroimage 58.3 (2011): 849-859.
- 38. James Clerk Maxwell. "A Treatise on Electricity and Magnetism: Volume 2". Cambridge Library Collection.

Volume 10 Issue 11 November 2018 © All rights reserved by G Broggi., *et al.*